ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
FDA Approves Pediatric Type 2 Diabetes Treatment
July 26, 2021The U.S. FDA approved Bydureon and Bydureon BCise (exenatide extended-release) injection to be used in addition to diet and exercise to improve glycemic control (blood sugar levels) in pediatric patients 10 years or older with type 2 diabetes. -
CFDA Approves New Once-Weekly Bydureon(R) to Improve Glycemic Control in Type-2 Diabetes Patients
January 05, 20183Sbio Incannounced today that China's first Glucagon-like peptide-1 receptor agonist weekly preparation Bydureon® has been formally approved by China Food and Drug Administration , as a new treatment option to improve glycemic control for patients with ty -
New injectable Bydureon BCise for type-2 diabetes patients approved by FDA
October 31, 2017New Bydureon formulation of once-weekly exenatide in an improved device provides significant HbA1c reduction with added benefit of weight loss.
Pharma Sources Insight January 2025
